Latest Zidovudine Stories

TITUSVILLE, N.J., March 27, 2012 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP, announced that the U.S. Food and Drug Administration (FDA) has approved INTELENCE® (etravirine) to be administered in combination with other antiretroviral (ARV) medications for treatment of human immunodeficiency virus 1 (HIV-1) in treatment-experienced pediatric patients (6 years to less than 18 years old) who are experiencing virologic failure with HIV-1 strains resistant to a...

A growing body of evidence underscores the importance of human gut bacteria in modulating human health, metabolism, and disease. Yet bacteria are only part of the story. Viruses that infect those bacteria also shape who we are. Frederic D. Bushman, PhD, professor of Microbiology at the Perelman School of Medicine at the University of Pennsylvania, led a study published this month in the Proceedings of the National Academy of Sciences that sequenced the DNA of viruses -- the virome -- present...

Mobile phones could play a valuable role in helping HIV patients to take their medication every day, according to a new Cochrane Systematic Review. The researchers found that patients were less likely to miss doses if they were sent weekly mobile phone text message reminders. Text messaging is increasingly being used as a means of support in health care, including to help promote attendance at clinics and hospitals, and to increase contact between patients and care workers. There is also...

WHAT: Results from two studies presented today at the 19th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle demonstrate the importance of identifying and treating HIV-infected infants within the first year of life both to prevent harm to the immune system and to enable normal neurological development. Although immediate ART during infancy benefits HIV-infected babies, the prospect of lifelong treatment raises numerous concerns, including the risk of drug side...

Leading AIDS experts at Johns Hopkins and other institutions around the world have issued new guidelines to promote entry into and retention in HIV care, as well as adherence to HIV treatment, drawn from the results of 325 studies conducted with tens of thousands of people infected with HIV, the virus that causes AIDS. The guidelines are believed to be the first ever to focus exclusively on how best to get those newly diagnosed with HIV into treatment plans and to help them adhere to...

A study of children and adolescents who had been infected perinatally (around the time of their birth) with human immunodeficiency virus (HIV) suggests little evidence of an association between specific antiretroviral therapy and the severity of psychiatric disorders, according to a report published Online First by Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals. A major concern for health professionals is the possibility that the severity of HIV illness...

New Approach Intended to Remove Barriers to Innovation in Drug Development WASHINGTON, Feb. 7, 2012 /PRNewswire-USNewswire/ -- As the war on HIV/AIDS begins its fourth decade, medical researchers, pharmaceutical manufacturers, patient advocates and government regulators face a new and unexpected scientific challenge: how to demonstrate the safety and efficacy of promising new antiretroviral drugs when the two traditional study designs - the superiority trial and the...

Better access to antiviral medications, support for treatment adherence and safer feeding options required to meet WHO goals, study finds Eliminating new infant HIV infections in Zimbabwe will require not only improved access to antiretroviral medications but also support to help HIV-infected mothers continue taking their medication and safely reduce or eliminate breastfeeding, according to an article in the January issue of PLoS Medicine. Findings of the report from an international...

RICHMOND, Calif., Jan. 9, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the initiation of two new Phase 2 clinical studies (SB-728-1101 and SB-728-902, Cohort 5) in its program to develop a "functional cure" for HIV/AIDS. Sangamo's ZFP Therapeutic(®)( )approach (SB-728-T) generates T-cells that are resistant to HIV infection using its zinc finger nuclease (ZFN) technology to permanently disrupt the DNA sequence encoding CCR5, a co-receptor used by...

Drug interactions weaken HIV drugs, could mutate virus New guidelines from the American Academy of Neurology will help physicians better choose seizure drugs for people on HIV/AIDS medication, avoiding deadly drug interactions and preventing critical anti-HIV drugs from becoming less effective, possibly leading to a more virulent strain of the disease. Michigan State University's Gretchen Birbeck – who spends several months each year in the sub-Sahara African nation of Zambia...